Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Viracta Therapeutics, Inc. (VIRX : OTC)

• Company Description    Viracta Therapeutics Inc. is a precision oncology company targeting virus-associated malignancies. The company is pursuing application of inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other virus-related cancers. Viracta Therapeutics Inc., formerly known as Sunesis Pharmaceuticals Inc., is based in SAN DIEGO. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $0.01 Daily Weekly Monthly 20 Day Moving Average: 133,933 shares Shares Outstanding: 39.74 (millions) Market Capitalization: $0.54 (millions) Beta: 1.06 52 Week High: $0.08 52 Week Low: $0.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.16% -22.19% 12 Week -14.56% -28.13% Year To Date -91.61% -92.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2533 S. COAST HWY. 101 SUITE 210 - CARDIFF,CA 92007 USA ph: 858-400-8470 fax: 650-266-3501 ir@viracta.com http://www.viracta.com

• General Corporate Information    Officers Mark Rothera - President and Chief Executive Officer Roger Pomerantz - Chairman Daniel Chevallard - Chief Operating Officer and Chief Financial Office Thomas Darcy - Director Ivor Royston - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92765F108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/24 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 39.74 Most Recent Split Date: 2.00 (0.29:1) Beta: 1.06 Market Capitalization: $0.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.18% vs. Previous Quarter: -8.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©